ABSTRACT
Objective To study the growth suppression effect of 131 I labeled anti KDR monoclonal antibody on the tumor tissue of human bladder cancer subcutaneously implanted in SCID mice. Methods The SCID murine model was established by subcutaneous implantation of human bladder cancer in mice. The 131 I labeled anti KDR monoclonal antibody (3G9) was injected into the caudal vein of mice (experimental group). The anti KDR monoclonal antibodies and saline were injected into the caudal vein of the mice (control group and blank group, respectively). The growth suppression effect of 131 I labeled anti KDR monoclonal antibody on the tumor tissue of SCID mice bearing human bladder cancer was observed. Results Tumor tissue necrosis was found in the mice of the experimental group and the control group at 3 weeks after the injection. Compared with that in the blank group, the growth suppression ratio in the experimental group and the control group were 96.8% and 87.7%, respectively. Conclusion 131 I labeled anti KDR monoclonal antibody may be of potential clinical significance in the anti angiogenesis therapy for human cancer.
ABSTRACT
Objective To quantitatively analyze type 1 receptor of insulin-like growth factors (IGF1Rs) on the HepG 2 cells. Methods 1H7 (monoclonal antibody against IGF1R) was labeled with radionuclide 131 I by Iodogen method. The mixture was purified with Sephadex G-50 column, 131 I-1H7, and its unlabeled counterpart 1H7 competitively bound to IGF1Rs on the HepG 2 cells. The average number of IGF1R on the HepG 2 cells was analyzed by Scatchard method. Results The Bmax of HepG 2 cells (2.0?10 5) in every well was 6.746?10 -12 mol/L. The expression of IGF1R on the HepG 2 cells was 2.03?10 4/cell. Conclusion IGF1Rs are expressed on the HepG 2 cells with high density and high affinity, which may be used in other related studies.